Long-term Efficacy and Safety of Ravulizumab in Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Final Analysis of the Phase 3 CHAMPION-NMOSD Trial (P7-1.012)

Sean Pittock; Michael Barnett; Jeffrey Bennett; Achim Berthele; Jérôme de Seze; Michael Levy; Ichiro Nakashima; Celia Oreja-Guevara; Jacqueline Palace; Friedemann Paul; Carlo Pozzilli; Kerstin Allen; Becky Parks; Ho Jin Kim

doi:10.1212/wnl.0000000000215493

June 9, 2026Neurology

Long-term Efficacy and Safety of Ravulizumab in Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Final Analysis of the Phase 3 CHAMPION-NMOSD Trial (P7-1.012)

View Full Paper

Ask AI

Bookmark

Share

Key Points

This trial aims to evaluate the long-term efficacy and safety of ravulizumab in patients with AQP4-Ab+ NMOSD.
Open-label, external placebo-controlled design
Final analysis from the CHAMPION-NMOSD trial (NCT04201262)
Focus on end-of-study results regarding efficacy and safety
End-of-study results indicating improved efficacy in the AQP4-Ab+ NMOSD population.
Safety profile demonstrates acceptable tolerability throughout the trial duration.

Implication

Phase 3 trial reports efficacy and safety of ravulizumab in AQP4-Ab+ NMOSD, highlighting its potential benefits.

Abstract

To report end-of-study efficacy and safety results from CHAMPION-NMOSD (NCT04201262), a phase 3, open-label, external placebo-controlled trial evaluating ravulizumab in AQP4-Ab+ NMOSD.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Pittock et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf403faef96ed7f05670b https://doi.org/10.1212/wnl.0000000000215493

View Full Paper

Ask AI

Bookmark

Share

Long-term Efficacy and Safety of Ravulizumab in Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Final Analysis of the Phase 3 CHAMPION-NMOSD Trial (P7-1.012)

Key Points

Implication

Abstract

Discussion

Cite This Study

Long-term Efficacy and Safety of Ravulizumab in Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Final Analysis of the Phase 3 CHAMPION-NMOSD Trial (P7-1.012)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading